Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (Nasdaq: SDGR) will present at Citi’s 17th Annual BioPharma Conference on September 7, 2022, at 10:30 a.m. ET. The management's discussion will be accessible via the company's website and archived for seven days. Known for its innovative physics-based software platform, Schrödinger enhances the discovery of therapeutics and materials, benefiting biopharmaceutical and industrial sectors globally. Founded in 1990, the company boasts over 700 employees and operates in more than 70 countries.

Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of inducement equity awards to newly appointed CFO, Geoffrey Porges. The inducement grants include a stock option for 180,000 shares and performance-based restricted stock units for 90,000 shares. The stock option has an exercise price of $28.55 per share, reflecting the closing price on August 18, 2022. The option vests over four years while performance units depend on achieving specified performance goals. This move aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's strategy to attract top talent.

Schrödinger, Inc. (Nasdaq: SDGR) has appointed Geoffrey Porges as chief financial officer, bringing over 30 years of experience in the biopharmaceutical industry. He will oversee financial operations, investor relations, and corporate affairs as well as strategic planning for the company's pharmaceutical collaborations. Porges, previously at SVB Securities, expressed excitement about contributing to Schrödinger's growth, highlighting a strong balance sheet and revenue outlook. The company's physics-based software platform is revolutionizing drug discovery, enabling faster and cost-efficient therapeutic development.

Schrödinger, Inc. (Nasdaq: SDGR) reported a 38.5 million total revenue for Q2 2022, reflecting a 29% increase from the previous year. Software revenue reached 30.0 million with a 25% rise, while drug discovery revenue surged 48% to 8.5 million. Despite strong revenue growth, the company reported a net loss of 47.7 million, compared to 35.0 million in Q2 2021. Schrödinger is set to begin Phase 1 clinical trials for its MALT1 inhibitor, SGR-1505, in Q4 2022 and maintains a solid cash position of 513 million.

Schrödinger (Nasdaq: SDGR) will disclose its second quarter 2022 financial results on August 4, 2022, after market closure. The company will also host a conference call at 4:30 p.m. ET, accessible via its investor website. Schrödinger, founded in 1990, has developed a physics-based software platform that accelerates the discovery of therapeutics and materials, reducing costs compared to traditional methods. The firm employs over 700 personnel and collaborates with partners globally, aiming to address unmet medical needs.

Schrödinger, Inc. (Nasdaq: SDGR) announced FDA clearance for its investigational new drug (IND) application for SGR-1505, a MALT1 inhibitor. Anticipated to begin a Phase 1 clinical trial in the second half of 2022, the study will target patients with relapsed or refractory B-cell lymphoma. The trial aims to assess the safety and effectiveness of SGR-1505. The company emphasizes the significant medical need for new treatments in this area, promising to explore combination therapies once the recommended dose is established.

Schrödinger, Inc. (Nasdaq: SDGR) is hosting its second annual Educator's Day to discuss the integration of computational tools in education. The event, featuring live webinars from esteemed educators, aims to equip K-12 and university students with modern scientific skills. Keynote speaker Maria Gallardo-Williams highlighted the effectiveness of virtual reality labs developed during the COVID-19 pandemic, which assisted over 50 universities. Schrödinger's software platform accelerates drug and materials discovery, emphasizing hands-on learning and bridging technology gaps in education.

Schrödinger (Nasdaq: SDGR) announced its participation in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 3:30 p.m. ET. The live presentation will be accessible in the investors section of Schrödinger's website and archived for seven days. Schrödinger is renowned for its innovative physics-based software platform that accelerates the discovery of therapeutics and materials, engaging biopharmaceutical and industrial sectors worldwide.

Schrödinger, Inc. (Nasdaq: SDGR) has appointed Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi, a former executive vice president at Red Hat, will also serve on the Audit Committee. His extensive experience in enterprise software is expected to support Schrödinger's growth and mission to enhance human health. Schrödinger specializes in a physics-based software platform that accelerates the discovery of therapeutics and materials, aiming to improve efficiency and reduce costs significantly compared to traditional methods.